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according to World Health Organization (WHO) grade, although the differences did not reach 
statistical significance (P= 0.32). The ratio of VASH-1/nestin-positive vessels, representing the 
maturation of neovessels, was also significantly higher in NET than in its nonneoplastic 
counterparts (P= 0.003). PRA and PRB immunoreactivity was detected more frequently in PNET 
than in other gastroenteropancreatic NET (P< 0.001, P< 0.001; respectively). PRA 
immunoreactivity was significantly lower in higher than lower grade PNET (P= 0.04) whereas 
CCND1 significantly elevated in higher grade PNET (P= 0.035). Significant difference was also 
confirmed in immunohistochemical analysis of PRA-CCND1 status among nonneoplastic and 
different WHO grades (P= 0.004). No significant correlation was detected between PRA and 
VASH-1/CD31 (P= 0.94). The proliferative activity of QGP-1 cell line with PRB expression, 
increased after administration of P4 (P= 0.006) whereas no significant changes detected in PRA 
transfected cells (P= 0.42). Results of my present study demonstrated that angiogenic activity 
was significantly increased with the vessel maturation decreased in NET with higher WHO grade. 
These structural changes in the vessels were considered to play an important role in inducing 
tumor-cell proliferation of NET. In addition, PRA could play an inhibitory role in cell 
proliferation in PNET by PRB inhibition under the presence of P4, which then probably 
decreased CCND1 expression. My results demonstrated that angiogenic process and PR 
expression were involved in independent pathways of NET biology in contrast to different 
neoplasms such as breast cancer, which could provide important information as to the 
development of potential therapeutic targets in the patients with NET. 
 
